Skip to main content

Advertisement

Log in

A Mucormycosis Case in a Cirrhotic Patient Successfully Treated with Posaconazole and Review of Published Literature

  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

Mucormycosis is an invasive fungal infection associated with a high mortality rate, especially in immunocompromised hosts. Mucormycosis rarely occurs in cirrhotic patients. Here, we report a case of mucormycosis with underlying liver cirrhosis and diabetes mellitus. The patient suffered from maxillary sinusitis and osteomyelitis, and the infection was successfully treated with antifungal agents, surgical debridement, and hyperbaric oxygen therapy. The antifungal treatments used were liposomal amphotericin B, itraconazole, and posaconazole. Although our patient had liver cirrhosis (Child-Pugh classification B), no hepatic decompensation was developed during the treatment course of posaconazole. This is the first report of the safe and effective use of posaconazole for the treatment of mucormycosis in a cirrhotic patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.

    Article  PubMed  Google Scholar 

  2. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–69.

    Article  PubMed  CAS  Google Scholar 

  3. Abbas Z, Jafri W, Rasool S, Abid S, Hameed I. Mucormycosis in patients with complicated cirrhosis. Singapore Med J. 2007;48:69–73.

    PubMed  CAS  Google Scholar 

  4. Pellicelli AM, D’Ambrosio C, Villani R, Cerasari G, Ialongo P, Cortese A, et al. Liver cirrhosis and rhino-orbital mucormycosis, a possible but rare association: description of a clinical case and literature review. Braz J Infect Dis. 2009;13:314–6.

    Article  PubMed  Google Scholar 

  5. Pillsbury HC, Fischer ND. Rhinocerebral mucormycosis. Arch Otolaryngol. 1977;103:600–4.

    Article  PubMed  CAS  Google Scholar 

  6. McNulty JS. Rhinocerebral mucormycosis: predisposing factors. Laryngoscope. 1982;92:1140–3.

    Article  PubMed  CAS  Google Scholar 

  7. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140–8.

    Article  PubMed  Google Scholar 

  8. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41:422–33.

    Article  PubMed  CAS  Google Scholar 

  9. Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastroenterol. 2007;41:403–11.

    Article  PubMed  Google Scholar 

  10. Christin L, Wysong DR, Meshulam T, Hastey R, Simons ER, Diamond RD. Human platelets damage Aspergillus fumigatus hyphae and may supplement killing by neutrophils. Infect Immun. 1998;66:1181–9.

    PubMed  CAS  Google Scholar 

  11. Sturtevant JE, Latge JP. Interactions between conidia of Aspergillus fumigatus and human complement component C3. Infect Immun. 1992;60:1913–8.

    PubMed  CAS  Google Scholar 

  12. Ruping M, Heinz WJ, Kindo AJ, Rickerts V, Lass-Florl C, Beisel C, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010;65:296–302.

    Article  PubMed  CAS  Google Scholar 

  13. Van Burik JAH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:E61–5.

    Article  PubMed  Google Scholar 

  14. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5:775–85.

    Article  PubMed  CAS  Google Scholar 

  15. Moton A, Krishna G, Ma L, O’Mara E, Prasad P, McLeod J, et al. Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. Curr Med Res Opin. 2010;26:1–7.

    Article  PubMed  CAS  Google Scholar 

  16. Torres-Narbona M, Guinea J, Martinez-Alarcon J, Munoz P, Pelaez T, Bouza E. Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. Med Mycol. 2008;46:225–30.

    Article  PubMed  CAS  Google Scholar 

  17. Branscomb R. An overview of mucormycosis. Lab Med. 2002;33:453–5.

    Article  Google Scholar 

  18. Ataseven H, Yuksel I, Gultuna S, Koklu S, Uysal S, Basar O, et al. Fatal rhinocerebral mucormycosis under the shade of hepatic encephalopathy. Ann Hepatol. 2010;9:462–4.

    PubMed  Google Scholar 

  19. Georgopoulou S, Kounougeri E, Katsenos C, Rizos M, Michalopoulos A. Rhinocerebral mucormycosis in a patient with cirrhosis and chronic renal failure. Hepatogastroenterology. 2003;50:843–5.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tun-Chieh Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, SY., Lu, PL., Tsai, KB. et al. A Mucormycosis Case in a Cirrhotic Patient Successfully Treated with Posaconazole and Review of Published Literature. Mycopathologia 174, 499–504 (2012). https://doi.org/10.1007/s11046-012-9561-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-012-9561-8

Keywords

Navigation